Headlines about Vascular Biogenics (NASDAQ:VBLT) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vascular Biogenics earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.5160980434378 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of research firms recently issued reports on VBLT. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, November 21st. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Finally, Chardan Capital upped their target price on Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $15.67.

Vascular Biogenics (NASDAQ VBLT) traded down $0.05 during mid-day trading on Thursday, reaching $6.90. The company had a trading volume of 296,300 shares, compared to its average volume of 161,300. Vascular Biogenics has a 12-month low of $3.90 and a 12-month high of $9.05.

WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/14/vascular-biogenics-vblt-given-media-impact-score-of-0-07.html.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Insider Buying and Selling by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Stock Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related stocks with our FREE daily email newsletter.